Abstract
Even though it is not yet a universally accepted, in our view, the best clinical practice in the case of operable luminal breast cancer is to begin systemic neoadjuvant hormonotherapy (HT) immediately after histologic diagnosis for the majority of patients. This strategy does not apply to patients with an indication for neoadjuvant chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Cancer Research & Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
